Biopharma firm Vyome Holdings posts Q2 net loss

Vyome Holdings

25/08/2026 13:23

Overview
US biopharmaceutical firm's Q2 net loss was $720,000, or $0.10 per share
Cash and cash equivalents rose to $7.9 mln as of June 30, 2026
Company advanced VT-1953 program and expanded pipeline with Impetis agreement

Outlook
Vyome plans further FDA engagement on VT-1953 clinical development via a Type C meeting
Company intends to advance new JAK inhibitor assets for autoimmune and inflammatory diseases
Vyome maintains focus on VT-1953 as primary development priority while expanding pipeline

Result Drivers
CLINICAL ADVANCEMENT - Co said it advanced its lead VT-1953 program, presenting Phase 2 data showing statistically significant improvements in malodor, daily life impact, and lesion pain, with no treatment-emergent adverse events
PIPELINE EXPANSION - Co in-licensed two selective JAK inhibitor assets via Impetis agreement, targeting autoimmune and inflammatory conditions
REGULATORY ENGAGEMENT - Co incorporated FDA feedback on VT-1953 clinical development and plans further engagement through a Type C meeting

Company press release: ID:nBw2XwQ5Ka

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.10
 

Reuters Recommended Reads
Aug 25 - Molecular Partners H1 net loss narrows on lower R&D expenses
Aug 25 - Stablecoin card spending forecast to hit $50 billion a year by 2028 - RedotPay
Aug 25 - US FDA expands approval for J&J's drug for rare blood disorder

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)